| First Author | O'Rourke M | Year | 2016 |
| Journal | PLoS One | Volume | 11 |
| Issue | 9 | Pages | e0162858 |
| PubMed ID | 27626928 | Mgi Jnum | J:254496 |
| Mgi Id | MGI:6099891 | Doi | 10.1371/journal.pone.0162858 |
| Citation | O'Rourke M, et al. (2016) Evaluating Tissue-Specific Recombination in a Pdgfralpha-CreERT2 Transgenic Mouse Line. PLoS One 11(9):e0162858 |
| abstractText | In the central nervous system (CNS) platelet derived growth factor receptor alpha (PDGFRalpha) is expressed exclusively by oligodendrocyte progenitor cells (OPCs), making the Pdgfralpha promoter an ideal tool for directing transgene expression in this cell type. Two Pdgfralpha-CreERT2 mouse lines have been generated for this purpose which, when crossed with cre-sensitive reporter mice, allow the temporally restricted labelling of OPCs for lineage-tracing studies. These mice have also been used to achieve the deletion of CNS-specific genes from OPCs. However the ability of Pdgfralpha-CreERT2 mice to induce cre-mediated recombination in PDGFRalpha+ cell populations located outside of the CNS has not been examined. Herein we quantify the proportion of PDGFRalpha+ cells that become YFP-labelled following Tamoxifen administration to adult Pdgfralpha-CreERT2::Rosa26-YFP transgenic mice. We report that the vast majority (>90%) of PDGFRalpha+ OPCs in the CNS, and a significant proportion of PDGFRalpha+ stromal cells within the bone marrow (~38%) undergo recombination and become YFP-labelled. However, only a small proportion of the PDGFRalpha+ cell populations found in the sciatic nerve, adrenal gland, pituitary gland, heart, gastrocnemius muscle, kidney, lung, liver or intestine become YFP-labelled. These data suggest that Pdgfralpha-CreERT2 transgenic mice can be used to achieve robust recombination in OPCs, while having a minimal effect on most PDGFRalpha+ cell populations outside of the CNS. |
